Citizens JMP maintains Market Perform rating on Adicet Bio stock

Investing.com - Citizens JMP analyst Reni Benjamin has reiterated a Market Perform rating on Adicet Bio Inc. (NASDAQ:ACET) following the company’s second-quarter 2025 financial results and corporate updates. According to InvestingPro data, the stock has declined nearly 51% over the past year, with current analyst consensus remaining cautiously optimistic.

Adicet Bio recently announced a strategic pipeline prioritization that included halting development of ADI-270 for clear cell renal cell carcinoma (ccRCC) and implementing a 30% workforce reduction, which could extend the company’s cash runway into the fourth quarter of 2026.

The company maintains a solid cash position of $125 million as it focuses on its autoimmune disease (AID) programs, with investors awaiting initial clinical data from these initiatives.

Citizens JMP remains on the sidelines pending further clinical validation of ADI-001’s efficacy in autoimmune conditions and ADI-212’s enhanced potency profile.

The research firm views Adicet Bio stock as fairly valued, citing no expected revenues or earnings in the near future, along with uncertainty regarding the timeline for pivotal studies in an evolving competitive landscape.

In other recent news, Adicet Bio has dosed the first patient with systemic sclerosis in the second cohort of its Phase 1 clinical trial for ADI-001, aimed at treating autoimmune diseases. The trial is also enrolling patients with lupus nephritis and systemic lupus erythematosus, with preliminary clinical data anticipated in the latter half of 2025. Meanwhile, H.C. Wainwright has initiated coverage on Adicet Bio with a Buy rating, setting a price target of $4.00. The focus of this coverage is on Adicet’s ADI-270, a therapy currently in a Phase 1 trial for CD70+ cancers. ADI-270 has received FDA Fast Track Designation for use in treating metastatic or advanced clear cell renal cell carcinoma, especially in patients previously treated with immune checkpoint and VEGF inhibitors. These developments highlight Adicet Bio’s ongoing efforts in both autoimmune and cancer therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.